DE69519997D1 - Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten - Google Patents

Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten

Info

Publication number
DE69519997D1
DE69519997D1 DE69519997T DE69519997T DE69519997D1 DE 69519997 D1 DE69519997 D1 DE 69519997D1 DE 69519997 T DE69519997 T DE 69519997T DE 69519997 T DE69519997 T DE 69519997T DE 69519997 D1 DE69519997 D1 DE 69519997D1
Authority
DE
Germany
Prior art keywords
treatment
autoimmune diseases
binding reagents
reagents against
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519997T
Other languages
English (en)
Other versions
DE69519997T2 (de
Inventor
Marcel Bonnefoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69519997(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9421463A external-priority patent/GB9421463D0/en
Priority claimed from GBGB9512480.6A external-priority patent/GB9512480D0/en
Priority claimed from GBGB9513415.1A external-priority patent/GB9513415D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69519997D1 publication Critical patent/DE69519997D1/de
Application granted granted Critical
Publication of DE69519997T2 publication Critical patent/DE69519997T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
DE69519997T 1994-10-25 1995-10-20 Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten Expired - Fee Related DE69519997T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9421463A GB9421463D0 (en) 1994-10-25 1994-10-25 Binding agents
GBGB9512480.6A GB9512480D0 (en) 1995-06-20 1995-06-20 Binding agents
GBGB9513415.1A GB9513415D0 (en) 1995-06-30 1995-06-30 Binding agents
PCT/EP1995/004109 WO1996012741A1 (en) 1994-10-25 1995-10-20 Binding agents to cd23

Publications (2)

Publication Number Publication Date
DE69519997D1 true DE69519997D1 (de) 2001-03-01
DE69519997T2 DE69519997T2 (de) 2001-06-21

Family

ID=27267444

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519997T Expired - Fee Related DE69519997T2 (de) 1994-10-25 1995-10-20 Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten

Country Status (21)

Country Link
US (2) US6627195B1 (de)
EP (3) EP0788514A1 (de)
JP (3) JPH10507460A (de)
KR (1) KR20040058016A (de)
CN (1) CN1171119A (de)
AT (1) ATE198895T1 (de)
AU (2) AU710369B2 (de)
BR (2) BR9509434A (de)
CA (2) CA2203364A1 (de)
DE (1) DE69519997T2 (de)
DK (1) DK0788513T3 (de)
ES (1) ES2154741T3 (de)
FI (1) FI971756A0 (de)
HK (1) HK1002765A1 (de)
HU (1) HU223006B1 (de)
IL (1) IL115733A (de)
MX (1) MX9702797A (de)
NO (1) NO971902L (de)
NZ (2) NZ295158A (de)
PT (1) PT788513E (de)
WO (2) WO1996012742A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
AU1960100A (en) * 1999-01-06 2000-07-24 Mcmaster University Method of preventing immune and hypersensitivity reactions
EP1239877B1 (de) * 1999-10-06 2008-01-09 Abbott GmbH & Co. KG Zusammensetzung enthaltend einen tnf-alpha inhibitor und einen integrin alphavbeta3 rezeptorantagonist
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
CN100460015C (zh) * 2003-02-14 2009-02-11 上海张江生物技术有限公司 免疫调节剂及其应用
JP2006522811A (ja) * 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
EP2322547A1 (de) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloidzellen-spezifisches Lectin
EP1733231B1 (de) * 2004-04-05 2011-05-04 Université Bordeaux 2 Peptide und peptidmimetika die an cd23 binden
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
US20090291048A1 (en) * 2005-10-25 2009-11-26 Baker Idi Heart And Diabetes Institute Holdings Limited Leukocyte-binding polypeptides and uses thereof
RU2489166C2 (ru) * 2006-04-09 2013-08-10 Джинентех, Инк. Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2496259B1 (de) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Behandlung von paroxysmaler nächtlicher hämoglobinurie
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
KR101813482B1 (ko) * 2010-11-24 2017-12-29 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 루푸스의 치료 또는 예방을 위한 조성물 및 방법
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
FR2599513B1 (fr) * 1986-05-27 1989-09-15 Unicet Laboratoires Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
GB8726230D0 (en) * 1987-11-10 1987-12-16 Rosen H Antibodies
EP0321842A1 (de) * 1987-12-22 1989-06-28 Kishimoto, Tadamitsu, Prof. Auflösbarer rekombinanter Fc-Rezeptor, dessen Herstellung und Verwendung
DE3830271A1 (de) * 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
WO1990004176A1 (en) * 1988-10-03 1990-04-19 Scripps Clinic And Research Foundation THE RECEPTOR BINDING REGION OF EBVgp350
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE912528A1 (en) * 1990-07-19 1992-01-29 Scripps Clinic Res Inhabition of mac-1 receptor binding fibrinogen using d30¹homologs
AU673499B2 (en) * 1991-07-25 1996-11-14 Biogen Idec Inc. Recombinant antibodies for human therapy
WO1993009803A1 (en) * 1991-11-22 1993-05-27 The Scripps Research Institute Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation
US5766943A (en) * 1992-08-17 1998-06-16 University Of Iowa Research Foundation DNA sequences for soluble form of CD23
EP0670734A4 (de) * 1992-10-09 1998-01-14 Blood Res Center Eine subpopulation von mac-1 (cd11b/cd 18) molekülen welche eine neutrophile adhäsion an icam-1 und fibrinogen vermitteln.

Also Published As

Publication number Publication date
EP1018517A2 (de) 2000-07-12
AU3867995A (en) 1996-05-15
JPH10507460A (ja) 1998-07-21
NZ295158A (en) 1999-09-29
AU710369B2 (en) 1999-09-16
HU223006B1 (hu) 2004-03-01
CN1171119A (zh) 1998-01-21
CA2203364A1 (en) 1996-05-02
HUT77572A (hu) 1998-06-29
EP1018517A3 (de) 2000-07-26
AU698158B2 (en) 1998-10-22
HK1002765A1 (en) 1998-09-18
PT788513E (pt) 2001-06-29
WO1996012742A1 (en) 1996-05-02
BR9509434A (pt) 1998-01-06
AU3843595A (en) 1996-05-15
WO1996012741A1 (en) 1996-05-02
BR9509498A (pt) 1997-12-23
ES2154741T3 (es) 2001-04-16
CA2203363A1 (en) 1996-05-02
US6627195B1 (en) 2003-09-30
US20040022783A1 (en) 2004-02-05
IL115733A (en) 1999-12-22
IL115733A0 (en) 1996-01-19
EP0788514A1 (de) 1997-08-13
NO971902D0 (no) 1997-04-24
DE69519997T2 (de) 2001-06-21
JP2001316291A (ja) 2001-11-13
EP0788513B1 (de) 2001-01-24
JPH09511757A (ja) 1997-11-25
EP0788513A1 (de) 1997-08-13
JP3323508B2 (ja) 2002-09-09
FI971756A (fi) 1997-04-24
ATE198895T1 (de) 2001-02-15
MX9702797A (es) 1997-06-28
NZ295352A (en) 1999-09-29
FI971756A0 (fi) 1997-04-24
DK0788513T3 (da) 2001-04-02
NO971902L (no) 1997-04-24
KR20040058016A (ko) 2004-07-02

Similar Documents

Publication Publication Date Title
DE69519997D1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
FI935585A0 (fi) Pyrrolopyrimidiner
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69009822D1 (de) Zusammensetzung und ihre Verwendung.
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
ATE229334T1 (de) Verwendung von crf-antagonisten
DE3875159D1 (de) Piperidylaminotriazin-derivate und ihre anwendung als stabilisatoren.
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE69132782D1 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
DE60212388D1 (de) 2-heteroaryl-imidazotriazinone und ihre verwendung bei der behandlung von entzündungs- oder immunerkrankungen
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
ATE124417T1 (de) 2,19-methylenoxy- und 2,19-methylenthiogebrückte steroide und ihre verwendung als inhibitoren von aromatase und 19-hydroxylase.
DE59003369D1 (de) Verwendung von Triacetin in Gleitmitteln.
DE69000237D1 (de) Bleichfixier-regenerationssatz und verwendung davon in photographischer behandlung.
ATE96857T1 (de) Verwendung von triacetin in gleitmitteln.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee